Windsong Radiology Group is now offering a new FDA-approved treatment for prostate cancer.
Xofigo (Radium 223 dichloride) is a new therapy used to treat prostate cancer that is resistant to other medical and surgical treatments that seek to lower testosterone levels in patients whose disease has spread to the bones.
Patients meeting certain criteria, including acceptable white blood cell and platelet counts, along with proven metastatic bone disease, may be eligible for up to six monthly infusions of this treatment.
Administration is very simple and side effects are minimal, said Dr. Thomas Summers, president of Windsong Radiology Group.
According to the American Cancer Society, prostate cancer is the most common type of cancer found in American men, other than skin cancer. Nearly 230,000 men will be diagnosed this year and nearly 29,500 will die from the disease in the U.S. If prostate cancer starts to spread to other areas of the body, it most commonly goes to the bones, which results in rapid tumor growth. The alpha particle-emitting isotope radium-223 mimics calcium and targets bone metastases. It is reported that patients who receive XOFIGO live longer, and demonstrate a delay in their first bone-related symptom or event.
For more information, call 631-2500, Ext. 2152, or visit xofigo-us.com.
Story topics: Shared